Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib

Distribution of KRASG12C Somatic Mutations across Race, Sex, and Cancer Type

(2021) Amin H. Nassar et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Prevalence and Concurrent Pathogenic Mutations of KRASG12C in Northeast Chinese Non-small-cell Lung Cancer Patients

(2021) Yan Liu et al.   Cancer Management and Research

Sotorasib for Lung Cancers with KRAS p.G12C Mutation

(2021) Ferdinandos Skoulidis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acquired Resistance to KRASG12C Inhibition in Cancer

(2021) Mark M. Awad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

(2020) Paul K. Paik et al.   NEW ENGLAND JOURNAL OF MEDICINE

Precision medicine in non-small cell lung cancer: Current applications and future directions

(2020) Soo-Ryum Yang et al.   SEMINARS IN CANCER BIOLOGY

Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies

(2020) Yoshiaki Nakamura et al.   NATURE MEDICINE

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors

(2020) David S. Hong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11

(2019) Linnéa La Fleur et al.   LUNG CANCER

KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition

(2019) Helen Adderley et al.   EBioMedicine

Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience

(2019) Badi El Osta et al.   Journal of Thoracic Oncology

Evaluation of Storage Tubes for Combined Analysis of Circulating Nucleic Acids in Liquid Biopsies

(2019) Aoife Ward Gahlawat et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer

(2019) Natasha B. Leighl et al.   CLINICAL CANCER RESEARCH

K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways

(2019) Matthias Scheffler et al.   Journal of Thoracic Oncology

Direct Ras G12C inhibitors: crossing the rubicon

(2019) Colin R. Lindsay et al.   BRITISH JOURNAL OF CANCER

Temporal and spatial effects and survival outcomes associated with concordance between tissue and blood KRAS alterations in the pan‐cancer setting

(2019) Kristina Mardinian et al.   INTERNATIONAL JOURNAL OF CANCER

BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale

(2019) Jillian Wilhelmina Paulina Bracht et al.   Cancers

Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors

(2019) Brian A. Lanman et al.   JOURNAL OF MEDICINAL CHEMISTRY

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors

(2018) Neal I. Lindeman et al.   Journal of Thoracic Oncology

OUP accepted manuscript

(2018)   ANNALS OF ONCOLOGY

Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

(2018) Shumei Kato et al.   CLINICAL CANCER RESEARCH

Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer

(2018) Vincent Bernard et al.   GASTROENTEROLOGY

Plasma ctDNA Analysis for Detection of the EGFR  T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer

(2017) Suzanne Jenkins et al.   Journal of Thoracic Oncology

Lung cancer: current therapies and new targeted treatments

(2017) Fred R Hirsch et al.   LANCET

Cost and Survival Analysis Before and After Implementation of Dana-Farber Clinical Pathways for Patients With Stage IV Non–Small-Cell Lung Cancer

(2017) David M. Jackman et al.   Journal of Oncology Practice

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer

(2016) Geoffrey R. Oxnard et al.   JOURNAL OF CLINICAL ONCOLOGY

Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆

(2016) Megan L. Hames et al.   LUNG CANCER

The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma

(2016) Anna Biernacka et al.   Cancer Genetics

Clinical Genotyping of Non–Small Cell Lung Cancers Using Targeted Next-Generation Sequencing: Utility of Identifying Rare and Co-mutations in Oncogenic Driver Genes

(2016) Laura J. Tafe et al.   NEOPLASIA

Prospective Validation of Rapid Plasma Genotyping for the Detection ofEGFRandKRASMutations in Advanced Lung Cancer

(2016) Adrian G. Sacher et al.   JAMA Oncology

Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses

(2015) T. K. Sundaresan et al.   CLINICAL CANCER RESEARCH

Statistical Consideration and Challenges in Bridging Study of Personalized Medicine

(2014) Meijuan Li   Journal of Biopharmaceutical Statistics